AbbVie stock slides 1.13% and underperforms competitors

8 articles · Updated · MarketWatch · May 7

Shares closed at $202.71 on Thursday, marking a third straight daily loss as the S&P 500 fell 0.38% and the Dow dropped 0.63%.
AbbVie lagged Johnson & Johnson, down 0.94%, Pfizer, down 0.19%, and Amgen, down 0.61% during the broader market sell-off.
The stock finished 17.20% below its 52-week high of $244.81 reached on 1 October, while trading volume of 6.3 million stayed below its 50-day average.

Analysts predict a 25% upside for AbbVie, yet the stock is falling. Is this a value trap or a golden buying opportunity?

With strong earnings but a falling stock, can AbbVie's new drugs truly overcome the loss of its blockbuster Humira?